EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tolerance and heteroresistance to echinocandins in Candida auris : conceptual issues, clinical implications, and outstanding questions

Erika Shor iD, David S Perlin iD, Dimitrios P Kontoyiannis iD

mSphere · 2025

DOI: 10.1128/msphere.00161-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift mSphere, 2025. Verfasst von Erika Shor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Candida auris, Candidiasis, Drug Resistance, Fungal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida auris is a significant public health threat due to its environmental persistence and multidrug resistance, with echinocandins being the preferred treatment. However, in addition to resistance, echinocandin tolerance and heteroresistance may contribute to treatment challenges. Echinocandin tolerance involves reduced drug-mediated killing, while heteroresistance is the ability of a small cell subset to grow at high drug concentrations. These phenomena may facilitate the emergence of full resistance and complicate clinical outcomes. The clinical significance of these mechanisms remains unclear, with limited data correlating them with treatment failures. Research is needed to understand their mechanisms and impact, develop streamlined and robust methods to detect them in clinical settings, and explore mitigation strategies. The pathogen’s range of drug adaptations demands innovative approaches like spatial transcriptomics to dissect these complex responses and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandida aurisCandidiasisDrug Resistance, FungalEchinocandinsHumansMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Candida aurisechinocandinsheteroresistancetolerance

Substanzen

Antifungal AgentsEchinocandins

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Erika Shor, David S Perlin, Dimitrios P Kontoyiannis

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Shor, E., Perlin, D. S., & Kontoyiannis, D. P. (2025). Tolerance and heteroresistance to echinocandins in Candida auris : conceptual issues, clinical implications, and outstanding questions. mSphere. https://doi.org/10.1128/msphere.00161-25

Vancouver

Shor E, Perlin DS, Kontoyiannis DP. Tolerance and heteroresistance to echinocandins in Candida auris : conceptual issues, clinical implications, and outstanding questions. mSphere. 2025. doi:10.1128/msphere.00161-25

BibTeX
@article{Shor2025,
  author = {Shor, Erika and Perlin, David S and Kontoyiannis, Dimitrios P},
  title = {Tolerance and heteroresistance to echinocandins in Candida auris : conceptual issues, clinical implications, and outstanding questions},
  journal = {mSphere},
  year = {2025},
  doi = {10.1128/msphere.00161-25}
}
Kostenlos starten →